Latest Axoltis News & Updates

See the latest news and media coverage for Axoltis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Axoltis

CNS regeneration company developing neurological drugs

axoltis.com
Headquarters
Lyon, France
Company type
Private company
Number of employees
15–50

Last updated

Latest news about Axoltis

In short: Axoltis raised €18 million and completed enrollment for its Phase 2 clinical trial of NX210c, a peptide targeting neurodegenerative diseases.

Company announcements

  • Axoltis

    Axoltis announces NX210c study publication

    The study, partnered with InSilicoTrials, shows encouraging results for relapsing-remitting multiple sclerosis. It leverages modeling tools for R&D in neurodegenerative diseases.

  • Axoltis

    Axoltis announces DSMB confirms NX210c safety

    The second review of the SEALS Phase 2 ALS trial shows satisfactory safety and tolerability in the first 50 patients. Topline results expected Q2 2026.

  • Axoltis

    Axoltis raises €18M Series A

    Funds accelerate NX210c development for ALS and neurodegenerative diseases. Trial results expected Q2 2026.

  • Axoltis

    Axoltis announces the inclusion of the last patient in the SEALS trial

    82 patients have been included in 16 centers since November 2024. Results are expected in April 2026. The trial evaluates NX210c to restore the blood-brain barrier in ALS. 🚀

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Axoltis

Track Axoltis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Axoltis competitors & trending companies

Browse news for competitors to Axoltis and other trending companies.